Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies

BackgroundSeveral RET-targeted agents, including highly selective RET inhibitors (SRIs) and multi-kinase inhibitors (MKIs), have been approved for the treatment of advanced medullary thyroid cancer (MTC). Despite these agents targeting the same pathway, direct comparative data is lacking. This study...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Jiazhong Wang, Gang Cao, Yang Liu, Hao Qiao, Qiao He, Bo Zheng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2026-06-01
coleção:	Frontiers in Endocrinology
Assuntos:	medullary thyroid cancer multi-kinase inhibitors network meta-analysis RET inhibitors selpercatinib
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fendo.2026.1851074/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!